Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2. Kaplan–Meier curves derived from data generated under study-specific assumptions. (A) Kaplan–Meier curves ... Figure 2. Kaplan–Meier curves derived.

Published bySpencer Gilmore Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2. Kaplan–Meier curves derived from data generated under study-specific assumptions. (A) Kaplan–Meier curves ... Figure 2. Kaplan–Meier curves derived."— Presentation transcript:

1 Figure 2. Kaplan–Meier curves derived from data generated under study-specific assumptions. (A) Kaplan–Meier curves ... Figure 2. Kaplan–Meier curves derived from data generated under study-specific assumptions. (A) Kaplan–Meier curves with the first-stage intervention ibrutinib plus obinutuzumab (IO) and the second-stage intervention ibrutinib maintenance (IM), for all simulated patients and for subgroups of simulated patients who did and did not achieve minimal residual disease negative with complete response (MRD- CR) status. (B) Kaplan–Meier curves with first-stage intervention ibrutinib plus venetoclax plus obinutuzumab (IVO) and second-stage intervention IM or IM discontinuation, for all simulated patients and for subgroups of simulated patients who did and did not achieve MRD- CR status. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Ann Oncol, Volume 30, Issue 4, 25 February 2019, Pages 542–550, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 1. SMART Schema. Both randomizations (R) use the use the initial stratification factors of baseline Rai stage ... Figure 1. SMART Schema. Both randomizations (R) use the use the initial stratification factors of baseline Rai stage (intermediate versus high) and FISH abnormality del(17)(p13.1) at baseline (present versus absent). Ibrutinib maintenance (IM) in stage 2 continues until disease progression, death, or unacceptable adverse events. Patients randomized to IM discontinuation would not receive any ibrutinib therapy following re-randomization. Embedded treatment regimen (1, 1) includes patients randomized to ibrutinib plus obinutuzumab followed by IM, regardless of minimal residual disease negative with complete response (MRD- CR) status; embedded treatment regimen (2, 1) includes patients randomized to ibrutinib plus venetoclax plus obinutuzumab followed by IM, regardless of MRD- CR status; embedded treatment regimen (2, 2) includes patients randomized to ibrutinib plus venetoclax plus obinutuzumab followed by IM for those who do not achieve MRD- CR status and IM discontinuation for those who do achieve MRD- CR status. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Ann Oncol, Volume 30, Issue 4, 25 February 2019, Pages 542–550, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3. Kaplan–Meier curves for each embedded treatment regimen, derived from data generated under study-specific ... Figure 3. Kaplan–Meier curves for each embedded treatment regimen, derived from data generated under study-specific assumptions. Embedded treatment regimen (1, 1) includes simulated patients in the ibrutinib plus obinutuzumab (IO) arm with ibrutinib maintenance (IM); embedded treatment regimen (2, 1) includes simulated patients in the ibrutinib plus venetoclax plus obinutuzumab (IVO) arm with IM, regardless of minimal residual disease negative with complete response (MRD- CR) status; embedded treatment regimen (2, 2) includes simulated patients in the IVO arm with IM for those who did not achieve MRD- CR status and IM discontinuation for those who did achieve MRD- CR status. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Ann Oncol, Volume 30, Issue 4, 25 February 2019, Pages 542–550, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 2. Kaplan–Meier curves derived from data generated under study-specific assumptions. (A) Kaplan–Meier curves ... Figure 2. Kaplan–Meier curves derived."

Similar presentations

Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.

Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Schematic representation of the experimental design.

Figure 1 Schematic representation of the experimental design.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.

Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...
bDMARD: biologic DMARD.

bDMARD: biologic DMARD.
Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.
RCTs: randomized controlled ...

RCTs: randomized controlled ...
Fig. 1 Graphical representation of improving mortality in stroke patients since the inception of a national stroke ... “Graph courtesy of George Dunn,

Fig. 1 Graphical representation of improving mortality in stroke patients since the inception of a national stroke ... “Graph courtesy of George Dunn,
Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.

Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.
Take home figure The protective role of CNP/NPR-B/NPRC.

Take home figure The protective role of CNP/NPR-B/NPRC.

Similar presentations

Ads by Google